Genmab A/S (NASDAQ:GMAB) Stock Price Expected to Rise, HC Wainwright Analyst Says

Genmab A/S (NASDAQ:GMAB) had its price objective lifted by investment analysts at HC Wainwright from $40.00 to $41.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 35.27% from the stock’s current price. HC Wainwright also issued estimates for Genmab A/S’s Q4 2025 earnings at $0.40 EPS, FY2025 earnings at $1.89 EPS, Q2 2026 earnings at $0.58 EPS, Q3 2026 earnings at $0.59 EPS, Q4 2026 earnings at $0.63 EPS and FY2026 earnings at $2.14 EPS.

Several other analysts have also weighed in on GMAB. Truist Financial reissued a “buy” rating and set a $48.00 price objective (down previously from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price on the stock in a report on Tuesday, September 23rd. Wall Street Zen lowered Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday. Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Finally, Zacks Research cut shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $39.75.

Genmab A/S Stock Up 4.3%

Shares of NASDAQ GMAB opened at $30.31 on Monday. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $33.65. The business has a fifty day simple moving average of $29.78 and a 200-day simple moving average of $24.62. The company has a market cap of $19.46 billion, a price-to-earnings ratio of 12.90, a P/E/G ratio of 1.51 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $975.40 million. Genmab A/S has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently made changes to their positions in the business. Headlands Technologies LLC boosted its position in shares of Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock worth $31,000 after purchasing an additional 1,464 shares during the last quarter. Osaic Holdings Inc. lifted its stake in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after buying an additional 440 shares during the period. CWM LLC grew its holdings in Genmab A/S by 50.5% during the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after purchasing an additional 603 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in shares of Genmab A/S by 124.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after buying an additional 1,070 shares during the period. Finally, AlphaCore Capital LLC bought a new stake in shares of Genmab A/S in the second quarter worth about $44,000. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.